Helix BioPharma Shareholders Approve All Resolutions at Annual Meeting

Helix BioPharma Corp. announced voting results from its Annual General and Special Meeting held on January 30, 2026, with shareholders demonstrating strong support for all proposed resolutions. A total of 61,885,815 common shares were voted at the meeting, representing 81.03% of the company's total issued and outstanding shares, indicating substantial shareholder engagement in the company's governance matters.

Shareholders voted overwhelmingly in favor of all items of business before the meeting, with each resolution receiving 99.99% approval from votes cast. The four director nominees listed in Helix's Management Information Circular dated December 15, 2025, were re-elected as directors of the company to hold office for the ensuing year. Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube each received 99.99% of votes in favor, with minimal withheld votes ranging from 3 to 563 shares across the four candidates.

The resolution to appoint Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting was approved with 99.99% of votes cast in favor. This appointment includes remuneration to be determined by the directors, maintaining continuity in the company's financial oversight and reporting processes.

A significant resolution regarding the amendment to the articles of the company to effect a consolidation of issued and outstanding common shares was approved with 99.99% support. The amendment authorizes a consolidation ratio selected by the directors of up to five pre-consolidation common shares for one post-consolidation common share, with the board authorized to determine the final consolidation ratio at its sole discretion. This authorization provides management flexibility in optimizing the company's capital structure as it advances its oncology pipeline.

A report on all items of business voted at the meeting will be filed on SEDAR+ at https://www.sedarplus.com. The company's forward-looking statements emphasize that actual results could differ materially from expectations due to numerous known and unknown risks and uncertainties, including assumptions proving incorrect, financing challenges, clinical trial delays or failures, third-party supplier issues, regulatory approval uncertainties, and general economic conditions. These risks are more fully described in the company's annual management's discussion and analysis for the year ended July 31, 2025 and Helix's Annual Information Form, available under the company's profile on SEDAR+ at https://www.sedarplus.com.

The voting results demonstrate shareholder confidence in Helix BioPharma's current leadership and strategic direction as the clinical-stage oncology company continues developing novel therapies for hard-to-treat cancers. The near-unanimous approval of all resolutions, particularly the share consolidation authorization, provides management with the mandate to pursue capital structure optimization while maintaining focus on advancing the company's pipeline, which includes the clinical-stage antibody-enzyme conjugate L-DOS47 for non-small cell lung cancer and other CEACAM6-expressing solid tumors.